Glaxosmithkline | GSK - DEBITO





DEBITO Cambiamento Data
AbbVie USD 67.5B 67.5B 2025-12
Amgen USD 54.6B 17M 2025-12
AstraZeneca USD 33.92B 4.3B 2026-03
Aurora Cannabis CAD 23.86M 76.48M 2026-03
Bausch Health Companies USD 20.85B 191M 2025-12
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Canopy Growth CAD 278.71M 19.38M 2026-03
Corcept Therapeutics USD 6.11M 251K 2025-12
Drreddys Laboratories INR 77.34B 9.61B 2026-03
Eli Lilly USD 42.5B 3.6M 2025-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 19.06B 1.31B 2026-03
J&J USD 47.93B 2.14B 2025-12
Merck USD 49.34B 7.97B 2025-12
Novartis USD 47B 11.62B 2026-03
Pacira USD 367.66M 4.53M 2026-03
Perrigo USD 3.64B 4.5M 2025-12
Pfizer USD 63.73B 231M 2026-03
Phibro Animal Health USD 474.17M 730K 2024-09
Prestige Brands USD 1.08B 38.27M 2025-12
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 20.33B 1.43B 2025-12
Supernus Pharmaceuticals USD 40.98M 1.23M 2025-12
Takeda JPY 4.85T 208B 2025-12
Teva Pharmaceutical Industries USD 17.09B 21M 2025-12
Zoetis USD 9.24B 1.96B 2025-12